MT Pharma America announces corporate name change

In 2009,  Mitsubishi Tanabe Pharma America, Inc. (MTPA)’s parent company, Mitsubishi Tanabe Pharma Corporation (MTPC) opened a new company with a focus on developing and commercializing novel compounds for the US market. Based in Jersey City, NJ, MT Pharma America officially launched in February of 2016 with the goal of developing therapies for some of the most difficult-to-treat diseases. On May 5, 2017, the US Food and Drug Administration approved RADICAVATM (edaravone), an intravenous infusion treatment indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS).1 RADICAVA will be commercialized in the US by MTPA.

"As we prepare to launch our first commercial product in the US, now is the appropriate time to fully align our corporate name with our parent company, MTPC, the world’s second oldest pharmaceutical company with more than 300 years of experience advancing innovative treatments," said Atsushi Fujimoto, President, Mitsubishi Tanabe Pharma America. "We are honored to be a part of this strong and impressive heritage as we commit ourselves to continued innovation in the US to meet patients’ unmet medical needs."

MTPA plans to pursue a robust pipeline of products with a priority focus on Central Nervous System (CNS) diseases, autoimmune diseases and diabetes.